Teva, In First-Ever CREATES Act Suit, Seeks Help With Fabry Disease Generic Development

 
• By Derrick Gingery

Amicus should to be forced to sell samples of Galafold (migalastat) for bioequivalence and other testing, Teva argues in what appears to be the initial case brought under the 2019 law intended to smooth the development of ANDAs.

Tip of the spear
In what could be the tip of the spear, Teva is attempting to become the first company to gain a court order to compel the sale of a brand drug for generic development. • Source: Alamy

More from Generics

More from Biosimilars & Generics